FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800689473> ?p ?o ?g. }

• W2800689473 endingPage "S129" @default.
• W2800689473 startingPage "S124" @default.
• W2800689473 abstract "Patients with active cancer have a heightened risk of venous thromboembolism (VTE). This risk is further increased by the initiation of chemotherapy. Although previous studies have suggested that the use of parenteral thromboprophylaxis in all ambulatory cancer patients receiving chemotherapy significantly decreases the rate of VTE, current clinical practice guidelines do not recommend routine use of thromboprophylaxis in this patient population. A major criticism of these studies has been the inclusion of patients at lower risk for VTE, which may have diluted the potential beneficial effect of the parenteral thromboprophylaxis. It is therefore imperative to appropriately risk stratify ambulatory cancer patients using a validated scoring system (e.g. Khorana risk score) in order to identify those most likely to benefit from thromboprophylaxis. Direct oral anticoagulants, such as apixaban, may offer a convenient and safe option for thromboprophylaxis. As such, AVERT will randomize 574 ambulatory cancer patients receiving chemotherapy who are at high-risk for VTE (as defined by a Khorana score of ≥2) to Apixaban 2.5 mg BID versus placebo. The primary study outcome will be the first episode of objectively documented symptomatic or incidental VTE (deep vein thrombosis and/or pulmonary embolism) within the first 6 months (180 days ± 3) following initiation of the blinded study drug for both intervention and placebo groups. The secondary safety outcomes include major bleeding, clinically relevant non-major bleeding, and overall survival rates. This study will hopefully offer evidence regarding the benefit of apixaban in ambulatory patients at high risk for VTE receiving chemotherapy." @default.
• W2800689473 created "2018-05-17" @default.
• W2800689473 creator A5027382439 @default.
• W2800689473 creator A5054511215 @default.
• W2800689473 creator A5071739915 @default.
• W2800689473 date "2018-04-01" @default.
• W2800689473 modified "2023-10-01" @default.
• W2800689473 title "Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial" @default.
• W2800689473 cites W1506072545 @default.
• W2800689473 cites W1506411149 @default.
• W2800689473 cites W1930681973 @default.
• W2800689473 cites W1971479905 @default.
• W2800689473 cites W1973509710 @default.
• W2800689473 cites W1975405040 @default.
• W2800689473 cites W1995391277 @default.
• W2800689473 cites W1996600303 @default.
• W2800689473 cites W1998788312 @default.
• W2800689473 cites W2003260150 @default.
• W2800689473 cites W2028673858 @default.
• W2800689473 cites W2031799746 @default.
• W2800689473 cites W2033377234 @default.
• W2800689473 cites W2033612873 @default.
• W2800689473 cites W2041113507 @default.
• W2800689473 cites W2045858611 @default.
• W2800689473 cites W2050624503 @default.
• W2800689473 cites W2059422995 @default.
• W2800689473 cites W2091265649 @default.
• W2800689473 cites W2091871712 @default.
• W2800689473 cites W2100184560 @default.
• W2800689473 cites W2134683286 @default.
• W2800689473 cites W2137283681 @default.
• W2800689473 cites W2141100626 @default.
• W2800689473 cites W2144666882 @default.
• W2800689473 cites W2150238019 @default.
• W2800689473 cites W2162193963 @default.
• W2800689473 cites W2162851198 @default.
• W2800689473 cites W2167494200 @default.
• W2800689473 cites W2196970594 @default.
• W2800689473 cites W2332736166 @default.
• W2800689473 cites W2490019007 @default.
• W2800689473 cites W2579916850 @default.
• W2800689473 cites W4252109704 @default.
• W2800689473 cites W4376595850 @default.
• W2800689473 doi "https://doi.org/10.1016/j.thromres.2018.01.018" @default.
• W2800689473 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29703470" @default.
• W2800689473 hasPublicationYear "2018" @default.
• W2800689473 type Work @default.
• W2800689473 sameAs 2800689473 @default.
• W2800689473 citedByCount "25" @default.
• W2800689473 countsByYear W28006894732018 @default.
• W2800689473 countsByYear W28006894732019 @default.
• W2800689473 countsByYear W28006894732020 @default.
• W2800689473 countsByYear W28006894732021 @default.
• W2800689473 countsByYear W28006894732022 @default.
• W2800689473 countsByYear W28006894732023 @default.
• W2800689473 crossrefType "journal-article" @default.
• W2800689473 hasAuthorship W2800689473A5027382439 @default.
• W2800689473 hasAuthorship W2800689473A5054511215 @default.
• W2800689473 hasAuthorship W2800689473A5071739915 @default.
• W2800689473 hasConcept C121608353 @default.
• W2800689473 hasConcept C126322002 @default.
• W2800689473 hasConcept C142724271 @default.
• W2800689473 hasConcept C177713679 @default.
• W2800689473 hasConcept C204787440 @default.
• W2800689473 hasConcept C27081682 @default.
• W2800689473 hasConcept C2776265017 @default.
• W2800689473 hasConcept C2776301958 @default.
• W2800689473 hasConcept C2776694085 @default.
• W2800689473 hasConcept C2778661090 @default.
• W2800689473 hasConcept C2779161974 @default.
• W2800689473 hasConcept C2780638905 @default.
• W2800689473 hasConcept C2908647359 @default.
• W2800689473 hasConcept C35785553 @default.
• W2800689473 hasConcept C71924100 @default.
• W2800689473 hasConcept C99454951 @default.
• W2800689473 hasConceptScore W2800689473C121608353 @default.
• W2800689473 hasConceptScore W2800689473C126322002 @default.
• W2800689473 hasConceptScore W2800689473C142724271 @default.
• W2800689473 hasConceptScore W2800689473C177713679 @default.
• W2800689473 hasConceptScore W2800689473C204787440 @default.
• W2800689473 hasConceptScore W2800689473C27081682 @default.
• W2800689473 hasConceptScore W2800689473C2776265017 @default.
• W2800689473 hasConceptScore W2800689473C2776301958 @default.
• W2800689473 hasConceptScore W2800689473C2776694085 @default.
• W2800689473 hasConceptScore W2800689473C2778661090 @default.
• W2800689473 hasConceptScore W2800689473C2779161974 @default.
• W2800689473 hasConceptScore W2800689473C2780638905 @default.
• W2800689473 hasConceptScore W2800689473C2908647359 @default.
• W2800689473 hasConceptScore W2800689473C35785553 @default.
• W2800689473 hasConceptScore W2800689473C71924100 @default.
• W2800689473 hasConceptScore W2800689473C99454951 @default.
• W2800689473 hasFunder F4320320150 @default.
• W2800689473 hasLocation W28006894731 @default.
• W2800689473 hasLocation W28006894732 @default.
• W2800689473 hasOpenAccess W2800689473 @default.
• W2800689473 hasPrimaryLocation W28006894731 @default.
• W2800689473 hasRelatedWork W2111281801 @default.
• W2800689473 hasRelatedWork W2312635070 @default.

• next